Analystreport

Crispr Therapeutics AG (NASDAQ: CRSP) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating.

CRISPR Therapeutics AG - Common Shares  (CRSP) 
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm Check Earnings Report
US:NASDAQ Investor Relations: nasdaq.com/symbol/crsp/real-time